Brief: Pharnext Announces PXT3003 Was Granted Priority Review By The China Food And Drug Administration
14/06/2018 06:36
June 14 (Reuters) - PHARNEXT SA PHARN.PA :
* PHARNEXT ANNOUNCES PXT3003 WAS GRANTED PRIORITY REVIEW BY THE CHINA FOOD AND DRUG
ADMINISTRATION
Source text for Eikon: ID:nBw7BXxX1a
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development